Much-debated university research deals backed by Amgen and Novartis appear on balance to have benefited the universities. But as they fade away, some observers predict that their kind will not be seen again
No takes yet. Share an insight, caveat, or question.
Andrew Lawler (2003) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: